glp-1 risks Medications: Everything You Need to Know Why do patients stop GLP-1

Description

Consumers are drinking less but with purpose

6,7 Multiple injectable peptidic GLP-1R agonists are approved for the treatment of type 2 diabetes mellitus (T2DM), 8 including liraglutide and semaglutide, 9 which are also approved for the treatment of obesity

It has the advantages of oral use, weight reduction, and potential positive cardiovascular effects in clinical practice

Potential benefits being investigated include: Cognitive performance : Some small-scale human studies have shown mixed results on cognitive tasks among participants receiving GLP-1 receptor agonists, with no consistent pattern of improvement established in randomised trials to date Cognitive decline : Observational data from diabetes cohorts suggest that patients prescribed GLP-1 agents may experience different rates of cognitive deterioration compared to those on other diabetes medications, though causality cannot be established Dementia risk : Population-based studies have indicated a possible association between GLP-1 receptor agonist use and dementia diagnoses, though these findings require confirmation in prospective trials Neuroimaging markers : Early research is examining potential effects on brain structure and function, but definitive evidence of preservation of brain volume has not been established Important limitations and considerations: Limited human trial data : Most evidence comes from animal models or observational studies

GLP-1 and GLP-1/GIP microdoses are lower-dose, provider-guided versions of GLP-1based therapies, when offered as part of our Ellie MD program, designed to support appetite regulation and metabolic wellness as part of a personalized care plan